These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28493502)

  • 1. Fasiglifam for glycaemic control in people with type 2 diabetes: A phase III, placebo-controlled study.
    Marcinak J; Cao C; Lee D; Ye Z
    Diabetes Obes Metab; 2017 Dec; 19(12):1714-1721. PubMed ID: 28493502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
    Marcinak JF; Munsaka MS; Watkins PB; Ohira T; Smith N
    Drug Saf; 2018 Jun; 41(6):625-640. PubMed ID: 29492878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2016 Sep; 18(9):925-9. PubMed ID: 27178047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial.
    Menon V; Lincoff AM; Nicholls SJ; Jasper S; Wolski K; McGuire DK; Mehta CR; Rosenstock J; Lopez C; Marcinak J; Cao C; Nissen SE;
    Diabetes Care; 2018 Dec; 41(12):2603-2609. PubMed ID: 30459247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
    Park J; Park SW; Yoon KH; Kim SR; Ahn KJ; Lee JH; Mok JO; Chung CH; Han KA; Koh GP; Kang JG; Lee CB; Kim SH; Kwon NY; Kim DM
    Diabetes Obes Metab; 2017 Dec; 19(12):1681-1687. PubMed ID: 28448688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
    Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
    Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A thorough QT/QTc study of the effect of fasiglifam, a GPR40 agonist, on cardiac repolarization in healthy adults.
    Lee RD; Nudurupati S; Marcinak J; Viswanathan P
    Clin Pharmacol Drug Dev; 2015; 4(3):175-83. PubMed ID: 27140797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
    Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
    Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
    Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.
    Kaku K; Katou M; Igeta M; Ohira T; Sano H
    Diabetes Obes Metab; 2015 Dec; 17(12):1198-201. PubMed ID: 26277887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.